Harmeet Sidhu
Geen lopende functies
Loopbaan van Harmeet Sidhu
Eerdere bekende functies van Harmeet Sidhu
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Hoofd Techniek/Wetenschap/O&O | - | - |
Ixion Biotechnology, Inc.
 Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | Operationeel Directeur | 01-12-2002 | - |
| President | 01-12-2002 | - |
Opleiding van Harmeet Sidhu
| Post Graduate Institute of Medical Education & Research | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 2 |
| Zweden | 2 |
| India | 2 |
Operationeel
| Chief Operating Officer | 1 |
| President | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Ixion Biotechnology, Inc.
Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | Health Technology |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Beurs
- Insiders
- Harmeet Sidhu
- Ervaring
